Clinical Study Evaluating Safety of Pentoxifylline and Celecoxib in Patients With Grand-Mal Epilepsy Treated by Phenytoin Monotherapy

Launched by MOSTAFA BAHAA · Nov 27, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the safety of two medications, Pentoxifylline and Celecoxib, in patients with grand mal epilepsy who are currently being treated with phenytoin, a common anti-seizure medication. The goal is to see if these additional medications can help improve the condition without causing harmful side effects. The trial is open to adults aged 18 and older who have been diagnosed with grand mal epilepsy and are only taking phenytoin for their treatment.

To participate, individuals must not have serious liver or kidney problems, be free from substance abuse, and should not have allergies to the medications being tested. The study is currently looking for participants, and those who join can expect regular check-ups and monitoring throughout the trial. It’s important to note that pregnant women or those planning to become pregnant cannot participate, as well as individuals using other anti-epileptic drugs. This study aims to provide valuable information on how these medications might work for epilepsy, contributing to better treatment options in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • - Patients aged ≥ 18 years old. Patients with grand mal epilepsy on phenytoin monotherapy. Women with a negative pregnancy test and women on effective contraception
• Exclusion Criteria:
• • - Patients with significant liver and kidney function abnormalities. Alcohol and/or drug abusers. Patients with known allergies to the study medications Patients with known allergy to sulfonamides (cross hypersensitivity with celecoxib).
• • Pregnant women and women with a planned pregnancy. Subjects on medication are known to have possible positive effects on epilepsy. Patients who are currently using other antiepileptic drugs. Patients with CVD and a history of coronary artery bypass graft (CABG) surgery. Patients on aspirin or fluconazole therapy Patients with a recent retinal or cerebral hemorrhage